The retail market for cough medicines (groups R05D and R05F) in Russia amounted to more than 9.8 billion rubles (at retail prices, including value-added tax) over January–October 2025. Total consumer spending in this category increased by 3.7 percent compared with the same period of 2024. Over ten months, Russian consumers purchased 25.8 million packages of medicines used for cough treatment; year-on-year, physical consumption within the group declined by 5.9 percent. The decline in unit sales has been observed for several consecutive years — since 2023, negative annual dynamics at the level of minus 6 percent have been recorded consistently.

In total, over the first ten months of 2025, the retail market (including the online channel) featured thirty-eight brands of cough medicines from thirty-five corporations. According to the “Audit of Retail Sales of Medicinal Products in Russia (total sell out)” database, the majority of brands available on the market exhibited a decrease in unit sales compared with January–October 2024, and in value terms, sixteen brands posted declining sales over the reporting period. Positive dynamics were primarily driven by new products introduced to the market in the past two years; over the last three years, six such brands have appeared. The most notable examples among the newcomers are the Russian brand Eladis from Valenta and the brand Syntus from Dominanta. Having debuted in early 2024, both brands demonstrated substantial growth: their demand increased tenfold and threefold, respectively, year-on-year.

In the ranking table for the first ten months of the current year, first place is retained by Rengalin from Materia Medica. At present, the product accounts for 33.3 percent of total consumer spending in the category; relative to January–October 2024, the brand exhibited growth of 7 percent in value terms, although its unit sales decreased by 5 percent. Second place is held by Herbion, produced by the Slovenian company KRKA, with a share of 11.7 percent (+12 percent in value). Closing the top three is Codelac from Otcpharm — during the reporting period the product accounted for 8.9 percent of the category’s value sales, with dynamics of +2 percent in value terms.

Notably, among the top ten brands, only three demonstrated growth in unit sales — these include the aforementioned Herbion (+3 percent), Bronchipret from Bionorica (+1 percent), and Bronholitin from Sopharma (+12 percent). The remaining brands showed declining sales, with the most pronounced decrease observed for Omnitus from Nizhpharm and for Grudnoy Sbor (Herbal Chest Mixture), produced by several companies — demand for both brands declined by 14 percent in unit terms year-on-year.

The strongest growth rates among cough medicines outside the top ten were recorded for the brand Primrose Syrup with Thyme from Vifitekh, introduced to the market in 2023. Compared with January–October of last year, sales of this product increased twenty-fourfold.

Table. Top 10 cough-medicine brands (groups R05D and R05F according to the EphMRA classification, excluding cold medicines) by value sales in the Russian retail pharmaceutical market in January–October 2025